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APOBEC3G and APOBEC3F restrict human immunodeﬁciency virus type 1 (HIV-1) replication in vitro
through the induction of G3A hypermutation; however, the relevance of this host antiviral strategy to clinical
HIV-1 is currently not known. Here, we describe a population level analysis of HIV-1 hypermutation in
near-full-length clade B proviral DNA sequences (n  127). G3A hypermutation conforming to expected
APOBEC3G polynucleotide sequence preferences was inferred in 9.4% (n  12) of the HIV-1 sequences, with
a further 2.4% (n  3) conforming to APOBEC3F, and was independently associated with reduced pretreat-
ment viremia (reduction of 0.7 log10 copies/ml; P  0.001). Defective vif was strongly associated with HIV-1
hypermutation, with additional evidence for a contribution of vif amino acid polymorphism at residues
important for APOBEC3G-vif interactions. A concurrent analysis of APOBEC3G polymorphism revealed this
gene to be highly conserved at the amino acid level, although an intronic allele (6,892 C) was marginally
associated with HIV-1 hypermutation. These data indicate that APOBEC3G-induced HIV-1 hypermutation
represents a potent host antiviral factor in vivo and that the APOBEC3G-vif interaction may represent a
valuable therapeutic target.
APOBEC3G (apolipoprotein B mRNA-editing enzyme, cat-
alytic polypeptide-like 3G) and the closely related APOBEC3F
are recently identiﬁed anthropoid-speciﬁc proteins that restrict
human immunodeﬁciency virus (HIV) type 1 (HIV-1) replica-
tion by deaminating cytosine residues in intermediary single-
stranded HIV DNA. This host antiviral strategy thereby intro-
duces DNA editing errors into the retroviral genome sequence,
resulting in the ﬁxation of an inordinate number of proviral HIV
DNA guanine-to-adenine (G3A) substitutions referred to as
hypermutation (10, 20, 43). Previous studies have deﬁned polynu-
cleotide motifs within single-stranded DNA that are preferen-
tially targeted by APOBEC3G (resulting in proviral DNA
GG3AG substitutions [substituted bases are underlined and ital-
icized]) and APOBEC3F (GA3AA) (2, 16, 36). These studies
have also identiﬁed HIV-1 viral infectivity protein (vif)a st h e
principal viral factor that counteracts APOBEC3-mediated DNA
editing by promoting the degradation of APOBEC3-vif com-
plexes via the proteasomal pathway (6, 21, 42). Recent in vitro
data also indicate that APOBEC3G and APOBEC3F are par-
tially resistant to vif (3), suggesting a more fundamental role for
these APOBEC3 proteins in directing HIV-1 genetic variation.
However, at present little is known of the disease-modulating
effects of APOBEC3G and/or APOBEC3F in HIV-infected pa-
tients, and it is uncertain if APOBEC3-mediated HIV DNA ed-
iting in vivo requires permissive conditions, such as defective vif
activity and/or APOBEC3 genetic variation. Here, we have uti-
lized near-full-length clade B HIV-1 proviral DNA sequences (an
average of 6,820  1,187 nucleotides/subject; total, 11,202 G3A
substitutions) from 127 HIV-infected, antiretroviral therapy-
naı ¨ve individuals to address each of these issues at a population
level.
MATERIALS AND METHODS
Patient selection. To be included in the study, pretreatment proviral HIV-1
DNA sequences were required to be of clade B (see below) and of sufﬁcient
length (1,000 nucleotides). These criteria allowed the inclusion of 136 adult
HIV-infected patients from the Western Australian HIV cohort (19), represent-
ing a predominantly Caucasian (84%) male (88%) population who had acquired
HIV infection through sexual contact (83%). All sequences were utilized in the
construction of the population consensus HIV-1 sequence in this study.
For the analysis of HIV-1 hypermutation based on proportions of nonconsen-
sus nucleotides representing G3A substitutions in one of the dinucleotide se-
quence contexts (GA, GG, GC, or GT), a further nine sequences with 77 or
fewer nucleotide substitutions from the consensus were omitted. These formed a
tight cluster of outliers disparate from the remainder of the sample and provided
potentially unstable estimates of the relevant proportions which could corrupt
results. Our analyses were thus based on 127 cases.
HIV-1 clade assignment. HIV sequences were analyzed by phylogenetic anal-
ysis using Molecular Evolutionary Genetic Analysis, version 3 (MEGA 3.0;
http://www.megasoftware.net) as follows. The nucleic acid sequences for the
individual HIV-1 protein products (e.g., p17, p24, and reverse transcriptase)
were extracted from the database. These were combined with 6 to 15 sequences
from each of clades A, B, C, D, and F as well as the sequence for HXB2 and the
M-group ancestral sequence; these reference sequences were downloaded from
the Los Alamos HIV sequence database. Phylogenetic trees were constructed
using the parameters (i) neighbor-joining tree inference, (ii) pairwise deletion,
* Corresponding author. Mailing address: Centre for Clinical Im-
munology and Biomedical Statistics, 2nd Floor, North Block, Royal
Perth Hospital, Wellington Street, Perth 6000, Western Australia.
Phone: 61 89 224 2899. Fax: 61 89 224 2920. E-mail: s.mallal@murdoch
.edu.au.










































































 and (iii) the Kumara two-parameter substitution model. The resulting trees were
then rooted on the M-group ancestral sequence and inspected. Most of the
sequences clearly sorted with reference sequences of a particular clade, and these
were assigned as belonging to that clade. Sequences that did not clearly belong
to a speciﬁc clade were assigned as unknown. A ﬁnal assignment of clade was
made based on the assignments for all of the proteins. If all of the protein
products for a particular patient were unambiguously assigned to the same clade,
then that sample was assigned to that clade. If all protein products were of the
same clade except for one protein product assigned as ambiguous, the consensus
clade was again assigned to that sample. Patient samples in which the proteins
belonged to several clades were noted as such (e.g., AB, BC) and excluded from
the study.
Ampliﬁcation and sequencing of HIV-1 proviral DNA, measurement of pre-
treatment HIV RNA levels, and HLA and CCR5 genotyping. Ampliﬁcation and
sequencing of HIV-1 proviral DNA, measurement of pretreatment HIV RNA
levels, and HLA and CCR5 genotyping were performed as previously described
in the work of Moore et al. (23). Patient DNA was extracted from blood samples
by use of a QIAGEN DNA extraction kit according to the manufacturer’s
instructions. The PCR conditions and primers used for the full-length ampliﬁ-
cation of the proviral HIV genome have been previously described (26). Brieﬂy,
the ﬁrst-round PCR was performed with an Expand long-template PCR kit
(Boehringer Mannheim) to produce a 9-kb ampliﬁed product. This ﬁrst round
product was then used as a template for 13 individual nested PCRs using Taq
polymerase (Boehringer Mannheim) to amplify the entire HIV genome from gag
p17 to the 3 long terminal repeat. First- and second-round PCRs were per-
formed on ABI 9700 and 9600 thermocyclers. Successfully ampliﬁed PCR prod-
ucts were sequenced in the reverse and forward directions using BigDye Termi-
nator ready reaction prism kits (v3). The samples were electrophoresed on an
ABI 3100 genetic analyzer, and sequencing data analyzed using ABI software
package Seqscape Version 1.1. Mixtures (sites where more than one nucleotide
was observed) were named according to the IUPAC standard. Sites that were
unable to be assigned were designated as “N” and excluded from the analyses.
Nucleotide sequence length within the study population averaged 6,820  1,187
nucleotides (range, 1,329 to 8,768 nucleotides).
Analysis of G3A substitutions. To estimate G3A substitutions, individual
HIV-1 proviral DNA sequences were aligned against the population consensus
clade B sequence (n  136). Only G3A substitutions where the nucleotide at
position 1 in the sample matched the corresponding nucleotide in the consen-
sus sequence were examined (where GA, GC, GG, and GT dinucleotides in the
consensus sequence were observed as AA, AC, AG, and AT, respectively, in the
sample sequence). Mixture nucleotide results obtained from chromatograph
analysis (indicating the presence of mixed nucleotide populations) were assigned
as missing values. To estimate “general” G3A hypermutation for each sequence
(i.e., without reference to the expected dinucleotide sequence context for
APOBEC3F or APOBEC3G), we incorporated two previously used measures of
hypermutation (27), G3A preference (#G3A substitutions/#all mutations,
where # indicates “number of”) and G3A burden (#G3A substitutions/
#consensus G) into a single formula:




This represents the proportion of all mutations that are G3A substitutions
adjusted for the proportion of nucleotides sequenced that are G in the consensus
sequence.
Analysis of APOBEC3G and APOBEC3F target motifs. To investigate the
contribution of APOBEC3G (3G) and APOBEC3F (3F) to hypermutation, we
examined the dinucleotide sequence contexts of G3A substitutions using the
following formulae:








These represent the proportion of all G3A substitutions that occurred in the
GG (APOBEC3G) and GA (APOBEC3F) contexts adjusted for the number of
available GG (APOBEC3G) and GA (APOBEC3F) dinucleotides.
Analysis of APOBEC3G-mediated hypermutation (HM-3G) and HM-3F. We
combined the hypermutation formula with either the 3G or the 3F formula to
identify sequences that had both an inordinate number of G3A substitutions
relative to other substitutions and a high preference for G3A substitutions
speciﬁcally in the sequence context targeted by either APOBEC3G or
APOBEC3F as follows:
Consolidated 3G score 
#GG3AG/#consensus GG)
#mutations/#nucleotides sequenced
Consolidated 3F score 
#GA3AA/#consensus GG
#mutations/#nucleotides sequenced
Thus, these represent the proportions of all mutations that were G3A substi-
tutions that occurred in the GG (consolidated 3G score) and GA (consolidated
3F score) dinucleotide contexts, adjusted for nucleotide availability in the con-
sensus sequence.
Histogram and Q-Q plots of the consolidated 3G values (log10 transformed)
suggested a bimodal distribution with a normally distributed main group and a
smaller group with higher values. The bimodal distribution was ﬁtted by a
mixture of two normal distributions using maximum likelihood, giving estimated
distributions with means  standard deviations (SD) of 0.277  0.151 and
0.417  0.151, respectively, with an estimated 9.0% of observations in the latter
group. The presence of a mixture was highly signiﬁcant (P 	 0.00005; likelihood
ratio test). The likelihood of belonging to the upper group was higher for the
largest 12 observations (9.4%), with one likelihood ratio of 8 and the rest greater
than 140. Hierarchical cluster analysis using between-group and centroid linkage
both gave two clear groups with numbers of 115 and 12, as did k-means cluster-
ing. The nonhypermutated (NH) group is approximately normal. Corresponding
cluster analyses of the non-APOBEC3G-hypermutated cases suggests three
cases with inordinate consolidated 3F values.
APOBEC3G allele frequencies. From eight participants with the highest G3A
hypermutation scores and a pooled DNA control sample (n  187 Caucasian
individuals) (32), the entire APOBEC3G gene, including 2 kb 5 of the tran-
scription start site and 1.0 kb 3 of the 3 untranslated region, was ampliﬁed as
two products of approximately 6.5 kb (3 half) and 8 kb (5 half) in size. For
ampliﬁcation of each product, 1 
l of DNA was ampliﬁed in a volume of 50 
l
containing 10 Hi-Fi PCR buffer, 2 mM MgSO4 (1.5 mM MgSO4 for the 3
half), 0.8 mM deoxynucleoside triphosphate mix, 100 nM of each forward and
reverse primer,1Uo fPlatinumTaq Hi-Fi, and 2% dimethyl sulfoxide (1.5% for
the 5 half) under the following conditions: 94°C for 30 s, followed by 35 cycles
of 94°C for 30 s, 63°C for 30 s (60°C for the 5 half), and then by a 9-min extension
step at 68°C. The PCR products were then puriﬁed using Exosap according to the
manufacturer’s protocol and sequenced using overlapping primers (see Table S1
in the supplemental material) and a BigDye Terminator kit, version 3.3 (PE,
Applied Biosystems). The allele frequencies of the pooled DNA sample were
determined by chromatograph relative peak height and compared to the allele
frequencies for the eight patients harboring the HIV-1 proviral sequence with
the greatest G3A hypermutation scores.
Statistical analysis. Statistical analyses were carried out using SPSS software
(version 12.0.1; SPSS Inc.). All values are expressed as means  standard devi-
ations unless otherwise stated. Where data were normally distributed, analysis of
variance was used for group comparisons, with correction for multiple compar-
isons utilizing the Bonferroni method where appropriate. For nonnormal data,
Mann-Whitney tests were used. The presence of in-frame stop codons in vif
amino acid sequences was determined by putative translation of the proviral
DNA sequences. With reference to analyses of the determinants of plasma HIV
RNA levels prior to antiretroviral therapy, HLA-B27 (n  7) and HLA-B58 (n 
4) were also considered as covariates along with HLA-B57 (n  12) and the
CCR532 genotype (n  25).
RESULTS
Analysis of G3A substitutions. We ﬁrst sought to ascertain
the population distribution of HIV-1 G3A substitutions in
order to identify hypermutated HIV-1 sequences within the
context of natural in vivo sequence variation. The study was
restricted to sequences identiﬁed as clade B by phylogenetic
analysis (n  127), involving a study population of predomi-
nantly male (87%) Caucasian (84%) patients with chronic
HIV-1 infection. All participants were antiretroviral therapy








































































 naı ¨ve at the time of clinical assessment and collection of pro-
viral HIV-1 DNA for sequencing, as reﬂected in the distribu-
tion of HIV RNA/ml viral load (mean  SD, 4.903  0.760
log10 copies), CD4
 T cell counts (380.6  298.3 cells/ml), and
percentage of CD4
 T cells (19.3%  10.9%). To investigate
G3A substitutions at the population level, we aligned each
individual’s HIV-1 proviral sequence to the population con-
sensus sequence and for each sequence considered two mea-
sures of hypermutation as previously described (27): (i) the
preference for G3A substitutions relative to all other substi-
tutions (deﬁned by the proportion of all mutations that were
G3A substitutions) and (ii) the burden of G3A substitutions
relative to the number of available consensus guanine nucleo-
tides (deﬁned by the proportion of consensus guanines that
exhibited G3A substitutions). As expected, we found that
G3A substitutions were the most common substitution ob-
served (median  interquartile range, 21.0%  4.0% of all
substitutions), and there was a highly signiﬁcant correlation
between G3A preference and G3A burden in the study
population (Spearman’s r  0.631; P 	 0.001), as shown in
Fig. 1A.
We then incorporated both G3A burden and G3A pref-
erence into a single index (general G3A hypermutation
score; see Materials and Methods) to ascertain if the distri-
bution of G3A substitutions conformed to a model in which
a proportion of sequences could be described as hypermu-
tated relative to natural sequence variation. Utilizing anal-
yses of population mixtures, these data were best described
by a bimodal mixed distribution rather than as data from a
single population (P 	 0.001), consistent with the hypothesis
that a proportion of proviral DNA sequences exhibited
HIV-1 hypermutation.
Analysis of APOBEC3G and APOBEC3F dinucleotide target
motifs. As mentioned previously, APOBEC3G and APOBEC3F
are known to target speciﬁc single-stranded polynucleotide DNA
motifs. Therefore, in order to further characterize and investigate
APOBEC3-associated HIV-1 hypermutation, we further exam-
ined the preference for G3A substitutions in the APOBEC3G
(GG) and APOBEC3F (GA) dinucleotide contexts. This was ﬁrst
accomplished by investigating the dinucleotide sequence context
for G3A substitutions (3G- and 3F-speciﬁc G3A substitution
scores; see Materials and Methods). Again, the population distri-
bution of the 3G-speciﬁc G3A substitution scores indicated the
presence of APOBEC3G-mediated G3A substitutions in a pro-
portion of sequences, in that there were two distinct clusters in the
distribution of GG3AG substitutions in the study population
(P 	 0.001) (Fig. 1B). In contrast, while there were three rela-
tively extreme 3F-speciﬁc G3A substitution scores, it was not
possible to demonstrate clear clusters (Fig. 1C).
Classiﬁcation of APOBEC3G- and APOBEC3F-hypermu-
tated HIV-1 sequences. In order to formally identify sequences
with evidence of HM-3G, we then analyzed the population
distribution of HIV-1 G3A substitutions incorporating both
(i) G3A preference relative to other mutations and (ii) pref-
erence for G3A substitutions within the GG context (consol-
idated 3G score; see Materials and Methods) (Fig. 2). Mixture
models and cluster analyses consistently identiﬁed 12 se-
quences (9.4%) that fulﬁlled these criteria (P 	 0.0005). As
shown in Table 1, these sequences exhibited a 1.9-fold pref-
erence for G3A substitutions on average and a 3.1-fold
increase in G3A burden compared with the remaining NH
sequences. In addition, 42.7%  8.7% of all G3A substi-
tutions were in the GG context, compared with 17.7% 
5.0% in the NH sequences. The average proportion of con-
sensus guanine bases that demonstrated G3A substitutions
in these hypermutated sequences (14.2%) was consistent
with previous descriptions of hypermutated HIV-1 proviral
FIG. 1. G3A substitutions in HIV-1 proviral DNA with inordinate G3A preference and G3A burden occur predominantly in the dinucle-
otide sequence contexts targeted by APOBEC3G (GG) and, to a lesser extent, in those targeted by APOBEC3F (GA). (A) G3A preference
(#G3A substitutions/all mutations) was highly signiﬁcantly correlated to G3A burden (#G3 substitutions/#consensus G) (r  0.853; P 	
0.001). (B and C) The general G3A hypermutation scores were signiﬁcantly correlated with the 3G-speciﬁc G3A substitution scores (r  0.318;
P 	 0.001) but not with the 3F-speciﬁc G3A substitution scores (r  0.065; P  0.465). Red shaded circles, HM-3G sequences determined by
mixed population analysis of the consolidated 3G score; black open triangles, HM-3F sequences determined by mixed population analysis of the
consolidated 3F score; blue open circles, NH sequences determined by mixed population analyses of the consolidated 3G and consolidated 3F
scores; †, general G3A hypermutation score (#G3A substitutions/#consensus G)/(#mutations/#nucleotides sequenced); *, 3G-speciﬁc G3A
substitution score (#GG3AG substitutions/#consensus GG)/(#G3A/#G); ‡, 3F-speciﬁc G3A substitution score (#GA3AA substitutions/
#consensus GA)/(#G3A/#G).








































































 DNA obtained from env gene sequences in vivo (16%) (15)
and utilizing vif virions in vitro (24).
Three additional sequences showed a strong preference for
HM-3F using these criteria (Table 1), with 59.9%  11.3% of
all G3A substitutions occurring in the GA context, compared
with only 26.1%  7.0% and 32.1%  6.0% in the HM-3G and
NH sequences, respectively.
While G3A substitutions were the most common substitu-
tion observed for the 112 NH sequences, there was no associ-
ation between the general G3A hypermutation score and the
3G-speciﬁc G3A substitution score (Pearson’s r  0.093; P 
0.331) or the 3F-speciﬁc G3A substitution score (r  0.140;
P  0.142). Hence, it is unlikely that APOBEC3G- or
APOBEC3F-mediated DNA editing contributes signiﬁcantly
to the rate of G3A substitutions (identiﬁed by bulk PCR
sequencing) within these nonhypermutated proviral DNA
sequences.
HIV-1 genomic distribution of G3A hypermutation. From
the data presented in Fig. 3, measures of general G3A hyper-
mutation (Fig. 3A), APOBEC3G-speciﬁc G3A substitutions
(Fig. 3B), and APOBEC3G-mediated hypermutation (Fig. 3C)
were distributed relatively evenly along the genome. Consis-
tent with results from Yu and colleagues (41), general G3A
hypermutation and APOBEC3G-mediated hypermutation
scores in HM-3G sequences were signiﬁcantly higher for pol
(P 	 0.001) than for gag (P  0.005); in contrast, however, they
were signiﬁcantly lower for env than for pol (P values for both
were 	0.001). Furthermore, consistent with results from
Wurtzer and colleagues (37), the distance from the central
polypurine tract was signiﬁcantly negatively correlated to the
general G3A hypermutation (r  0.283; P  0.007), 3G-
speciﬁc G3A substitution (r  0.250; P  0.020), and con-
solidated 3G (r  0.297; P  0.006) scores.
Association of vif amino acid polymorphisms and G3A
hypermutation. We subsequently sought to investigate associ-
FIG. 2. The consolidated 3G scores reﬂect a bimodal distribution.
The bimodal distribution of the consolidated 3G scores [(#GG3GA/
#consensus GG)/(#mutations/#nucleotides sequenced)] was ﬁtted by
a mixture of two normal distributions utilizing maximum likelihood,
giving estimated distributions with means  SD of 0.277  0.151
(blue shaded bars; subsequently deﬁned as NH sequences) and 0.417 
0.151 (red partially shaded bars; subsequently deﬁned as HM-3G se-
quences), respectively. The presence of a population mixture was
highly signiﬁcant (P 	 0.0005; likelihood ratio test).
TABLE 1. Patient and sequence characteristics of patients harboring putative APOBEC3G-hypermutated,
APOBEC3F-hypermutated, and nonhypermutated HIV-1 proviral DNA
Characteristic or score




No. 112 12 3
CD4
 count (cells/ml) 367.2  306.1 491.3  236.7 421.3  152.1
CD4
 percentage 18.5  10.7 24.7  11.4 28.3  8.3
Viral load (log10 copies/ml) 4.981  0.747 4.476  0.50* 3.721  0.680*
HIV-1 sequence characteristics
No. of nucleotides sequenced per patient 6,906  1,016 6,571  1,549 4,591  3,182
No. of non-G3A mutations 290  66 295  97 246  129
No. of G3A substitutions 75  18 210  107 110  40
G3A rate (per 100 nucleotides) 1.08  0.21 3.4  1.8 3.3  2.4
G3A substitutions: all substitutions 0.206  0.029 0.40  0.123 0.321  0.049
G3A burden (% of consensus G’s) 4.6  0.9 14.2  7.5 14.9  11.4
GG( %o fG 3A substitutions)
b 17.7  5.0 42.7  8.7 10.8  5.2
GA( %o fG 3A substitutions)
b 32.1  6.0 26.1  7.0 59.9  11.3
Hypermutation scores
c
General G3A hypermutation 0.06  0.06 0.22  0.11 0.14  0.08
3G-speciﬁc G3A substitutions 0.21  0.13 0.19  0.11 0.45  0.25
3F-speciﬁc G3A substitutions 0.05  0.08 0.15  0.11 0.22  0.06
Consolidated 3G 0.28  0.15 0.41  0.16 0.30  0.16
Consolidated 3F 0.12  0.11 0.07  0.15 0.36  0.15
a Numbers are expressed as means  standard deviations where appropriate. *, 	5% signiﬁcance level compared to NH sequences.
b GG and GA represent percentages of G3A substitutions that occurred in the GG and GA dinucleotide contexts, respectively.
c See Materials and Methods for log10 transformed values; signiﬁcance not determined for HIV-1 sequence characteristics or hypermutation scores, as these were
the basis of the classiﬁcations.








































































 ations between vif amino acid polymorphisms and hypermuta-
tion. For such analyses, we performed a putative translation of
available vif sequences (n  124) and examined vif polymor-
phism within the NH sequences (vif amino acids 1 to 193)
compared with the corresponding amino acid in the HM-3G
sequences. HM-3F sequences were omitted from these analy-
ses so that speciﬁc associations relevant to the APOBEC3G-vif
interaction could be examined, as it has recently been reported
that speciﬁc vif amino acid polymorphisms differentially inﬂu-
ence APOBEC3G versus APOBEC3F interaction (31).
vif peptide sequences derived from the HM-3G group were
signiﬁcantly different from NH vif sequences in terms of a
higher overall rate of nonconsensus amino acids (P 	 0.0005;
Mantel-Haenszel). The strongest associations were trypto-
phan-to-in-frame stop substitutions at positions 70, 89, 174,
and 21 and substitution of isoleucine for the methionine start
codon (all Pc [corrected P] values were 	0.04 by the Bonfer-
roni method). These substitutions, which would be anticipated
to code for truncated and functionally defective vif proteins,
are all in the trinucleotide sequence context targeted by
APOBEC3G (TGG) and therefore are likely to have resulted
from, rather than caused, HIV-1 hypermutation. HM-3G se-
quences were also associated with an R90K polymorphism (Pc
 0.07; Bonferroni); again, however, this could be attributed to
the action of APOBEC3G. No other vif polymorphisms were
found to be signiﬁcantly associated with APOBEC3G-associ-
ated hypermutation (all Pc values were 0.4).
Regarding the potential role of truncated vif sequences in
permitting APOBEC3G-mediated HIV-1 hypermutation, it is
notable that while HM-3G sequences were signiﬁcantly asso-
ciated with in-frame stop codons speciﬁcally in vif (P 	 0.001),
in-frame stop codons in non-vif or non-vif, non-env proteins
were not associated with HM-3G sequences (P values were
0.20 and 0.63, respectively). Additionally, HIV-1 hypermuta-
tion was not evident in the two sequences in which the only vif
in-frame stop codon was at vif amino acid position 153
FIG. 3. General G3A hypermutation [(#G3A substitutions/#consensus G)/(#mutations/#nucleotides sequenced)], 3G-speciﬁc G3A sub-
stitutions [(#GG3AG substitutions/#consensus GG)/(#G3A/#G)], and consolidated 3G [(#GA3AA substitutions/#consensus GA)/(#G3A/
#G)] scores were relatively constant along the HIV-1 genome. Red shaded circles, HM-3G sequences; blue open circles, NH sequences; x axis,
nucleotide position relative to HXB2 (GenBank accession number K03455). y axis values are log10 transformed; curves are locally weighted (Loess)
smoothers.








































































 (leucine) or 174 (tryptophan). In these sequences, G3A sub-
stitutions accounted for only 20.7% and 24.9% of all substitu-
tions, affecting only 4.0% and 5.0% of consensus guanine res-
idues, respectively. It has previously been demonstrated that a
naturally occurring vif protein truncated at tryptophan
174 is
indistinguishable from wild-type vif in terms of the mainte-
nance of viral infectivity (25). Here, the occurrence of a natu-
rally occurring vif protein truncated at leucine
153 also suggests
that the C-terminal 39 amino acids are dispensable for this
protein’s roles in promoting viral infectivity as well as counter-
acting APOBEC3G. Interestingly, despite the codon for tryp-
tophan being a target for APOBEC3G, tryptophan residues 5,
11, and 79 were entirely conserved in the hypermutated vif
sequences and are therefore unlikely to play a role in inhibiting
APOBEC3G or APOBEC3F activity, in contrast to data from
Tian and colleagues (33).
We also identiﬁed vif polymorphisms that were unique to the
HM-3G sequences within this study population, given previous
evidence that sequence variation at a number of critical resi-
dues can affect vif-APOBEC3G interactions (29, 35). Twenty-
three vif amino acid variants were found uniquely in HM-3G
sequences (see Fig. 5), of which 82% were within regions
previously shown to be required for vif-APOBEC3G interac-
tion (29, 35). Of these, 13 could not have resulted from an
APOBEC3G-mediated G3A substitution of the NH consen-
sus amino acid, all of which were located within the vif N
terminus. It is also interesting that a charged consensus amino
acid was present in 14/23 of these positions and that the variant
vif sequence was frequently associated with either a reversal of
the charge state (6/14, 43%) or substitution of a neutral amino
acid (3/14, 21%). An additional three vif amino acids were
unique to the two HM-3F vif sequences available and also
could not have resulted from a G3A substitution of any of the
alternative amino acids present in the NH sequences. Again,
two of the HM-3F unique amino acids were located within the
vif N terminus (L
98 and S
103).
Figure 4 demonstrates the high degree of vif polymorphism
that appears to be tolerated without apparently increasing viral
susceptibility to the effects of APOBEC3G and/or APOBEC3F.
Within the nonhypermutated group, polymorphism was ob-
served at the serine
144 and leucine
148 residues (underlined) of
the SOCS-box N-terminal BC-box motif (
144SLQYLA
149)r e -
FIG. 4. The consensus vif amino acid sequence of the nonhypermutated sequences. The consensus sequence of the nonhypermutated sequences
shown here was identical to the consensus vif sequence of the hypermutated HIV-1 sequences. To determine the consensus amino acid sequence,
individual sequences were putatively translated, and the most common amino acid at each location was deemed the consensus. Blue bars indicate
frequencies of nonconsensus amino acids. Underlined letters indicate previously described motifs, with open bars indicating the frequency of
nonconsensus amino acids at these sites. See the text for references regarding vif regulatory motifs. Numbers indicate vif amino acid numbers. ,
stop codon; 1, Fujita et al., 2004 (reference 8); 2, Mehle et al., 2004 (reference 22); 3, Yang et al., 2003 (reference 39); 4, Ochsenbauer et al., 1996
(reference 25).








































































 quired for vif phosphorylation (40) and Elongin BC and Cul5
binding (22), respectively, and at the proline
162 (1.0%) residue
of the SOCS-box C-terminal motif
161PPLP
164, required for vif
multimerization and subsequent vif function (39). In contrast,
the existence of polymorphism at these sites in our population
suggests that they may not be essential for maintaining vif
function. However, the recently described Hx5Cx17-18Cx3-5H
zinc-binding motif (38), critical for assembly and activity of the
vif-Cul5-E3 ligase (18), was entirely conserved.
APOBEC3G genetic variation and G3A hypermutation. To
assess the contribution of APOBEC3G genetic variation to
hypermutation, we sequenced the entire 10.5-kb APOBEC3G
gene, including 2 kb 5 of the transcription start site and 0.5 kb
3 of the 3 untranslated region. We initially compared the
frequency of APOBEC3G alleles from eight patients with the
greatest G3A burden to that estimated from a pooled DNA
sample (187 Caucasian individuals) (32) as a control, based on
relative chromatogram peak height. As demonstrated in Table 2,
the APOBEC3G amino acid sequence was highly conserved in
this predominantly Caucasian study population. Of the 22 sin-
gle nucleotide polymorphisms (SNPs) identiﬁed (17 previously
described and 5 novel SNPs), signiﬁcant differences in allele
frequencies between the patients with hypermutated se-
quences and the pooled DNA control sample were evident at
positions 625 (9607609) and 6,892 (5757467) relative to the
transcription start site (Table 2). We then genotyped the 625
and 6,892 SNPs for patients that had DNA available (n  119).
The frequency of the 6,892 C allele tended to be higher in
patients with evidence of APOBEC3G-mediated hypermuta-
tion (50.0% versus 29.9%; P  0.062), with homozygosity for
the 6,892 C allele present in 25% of patients with evidence of
APOBEC3G-mediated hypermutation compared with 7.5% of
patients with nonhypermutated sequences (P  0.082). How-
ever, this marginally signiﬁcant univariate association was ab-
rogated after adjusting for multiple comparisons (Pc  0.5).
The frequencies of the 625 C allele were similar for patients
with evidence of APOBEC3G-mediated hypermutation and
for patients harboring NH sequences (allele frequency, 75.0%
versus 77.2% [P  0.80]; CC genotype frequency, 58.3% versus
57.3% [P  1.0]).
G3A hypermutation and HIV-1 viremia. The biological and
clinical relevance of HIV-1 hypermutation in proviral DNA
sequences is ultimately a function of its impact on productive
HIV infection, measured by the level of viremia in plasma
samples. We therefore sought to investigate the effect of
HIV-1 hypermutation on pretreatment viremia in this study
population. Univariate analysis indicates that patients harbor-
ing hypermutated sequence as deﬁned had viral loads signiﬁ-
cantly lower than those with nonhypermutated sequence (4.32 
0.60 versus 4.98  0.75 log10copies HIV RNA/ml; P  0.001).
By use of linear regression models, this association between
hypermutation and lower pretreatment viremia remained






d: No. of HM-3G patients
that were
e:
Control sample Allele 2 from the work
of Do et al. (7)
HM-3G patient
A1.A1 A1.A2 A2.A2
Allele 1 Allele 2 Allele 1 Allele 2
7291971 1,193 0.60 0.40 0.40 0.44 0.56 2 3 3
6519166 1,190 0.70 0.30 0.31 0.56 0.44 2 5 1
5750743 321 0.50 0.50 0.28 0.44 0.56 1 5 2
12160242 480 0.90 	0.10 0.09 0.94 0.06 7 1 0
9607609 625 0.80 0.20 ND 0.38 0.62 2 2 4
5757465 3,756† 0.60 0.40 0.51 0.75 0.25 4 4 0
12158985 5,985 0.90 	0.10 0.07 0.88 0.12 6 2 0
2294366 5,986 0.70 0.30 0.34 0.56 0.44 2 5 1
2294367 6,207 0.60 0.40 0.42 0.44 0.56 2 3 3
NL 6,848 0.90 	0.10 ND 0.88 0.12 6 2 0
3091374 6,878 0.50 0.50 ND 0.44 0.56 2 3 3
5757467 6,892 0.70 0.30 ND 0.31 0.69 0 5 3
5757468 6,893 0.70 0.30 ND 0.56 0.44 2 5 1
NL 6,894 0.90 	0.10 ND 0.88 0.12 6 2 0
NL 8,984‡ 0.90 	0.10 ND 0.88 0.12 6 2 0
5757471 9,218 0.90 	0.10 ND 0.94 0.06 7 1 0
28474760 9,250 0.90 	0.10 0.07 0.88 0.12 6 2 0
28474761 9,432 0.90 	0.10 0.12 0.88 0.12 6 2 0
NL 10,393 0.50 0.50 ND 0.92 0.08 5 1 0
NL 10,399 0.70 0.30 ND 1.00 0.0 8 0 0
5757472 10,600 0.50 0.50 ND 0.44 0.56 1 5 2
3891126 10,811 0.90 	0.10 ND 0.88 0.12 6 2 0
a Comparisons with a pooled DNA control sample and with results from a published study are shown. Results in boldface are those for which signiﬁcant differences
in allele frequencies between patients with hypermutated sequences and the pooled DNA control sample were evident.
b NCBI dbSNP ID, National Center for Biotechnology Information SNP database reference number. NL, novel SNP.
c Positions are relative to the transcription start site with reference to NCBI accession number NT_011520. †, synonymous SNP; ‡, nonsynonymous SNP.
d Allele frequencies of the pooled DNA sample were estimated by chromatogram relative peak height. Signiﬁcant differences in the allele frequencies of the 625 and
6,892 SNPs were evident between the hypermutated patients and the pooled DNA sample. A result of 	0.10 indicates that allele frequency was below the limit of
detection. ND, not determined.
e A1.A1, homozygous for allele 1; A1.A2, heterozygous; A2.A2, homozygous for allele 2.








































































 highly signiﬁcant (P  0.013) even after adjusting for CD4

percentage (P 	 0.001) and presence of at least one of the
known protective host alleles, CCR532 (17), HLA-B57, HLA-
B58,o rHLA-B27 (9) (P  0.096), and approximates 67% and
40% reductions in viral loads attributable to hypermutation
and host protective alleles, respectively. Hence, the clinical
inﬂuence of HIV-1 hypermutation appears to be demonstrable
within this group of patients, who manifest a marked preference
for G3A substitutions in an APOBEC3G or APOBEC3F se-
quence context.
DISCUSSION
The data presented in this population-based study of clade B
HIV-1 sequences suggest that HIV-1 G3A hypermutation is a
prevalent phenomenon associated with signiﬁcantly reduced
plasma HIV RNA levels in vivo, indicating that APOBEC3G-
and APOBEC3F-mediated hypermutation can take its place
alongside other protective host genetic factors as a clinically
and biologically relevant antiretroviral restriction factor. In-
deed, the reduced HIV-1 viremia associated with hypermuta-
tion was substantially greater than that exerted by known host
factors, such as the CCR532 chemokine receptor variant, and
remained highly signiﬁcant after adjusting for these variables
as well as for the inﬂuence of CD4
 count. Such reductions in
viral load are substantially greater than those previously asso-
ciated with protective HLA alleles (28) and are comparable to
the effects of zidovudine monotherapy in early studies of an-
tiretroviral treatment (4).
Here, it was estimated that hypermutated proviral DNA was
present in 12% of study participants by use of a bulk PCR
sequencing approach that approximates the dominant species
within a heterogeneous viral population. In many respects,
these ﬁndings complement the work of Kieffer and colleagues
(14), who examined the phenomenon of in vivo hypermutation
in detail utilizing 319 pol clones derived from nine patient
samples. This study revealed at least one hypermutated provi-
ral DNA sequence from each individual examined, although
hypermutated sequences accounted for less than 10% of the
proviral population within an individual. Similar results have
been obtained by Janini et al. (11), who detected the presence
of G3A hypermutation in 45% of HIV protease sequences
from a Tanzanian study population. These observations are con-
sistent with in vitro data demonstrating low-level APOBEC3G-
and APOBEC3F-mediated cytidine deaminase activity directed
against HIV-1 sequences even in the presence of functional vif
(13, 21). It has also been suggested that the rapid turnover of vif
through proteasomal degradation contributes to constitutively
low cellular protein expression (34), thereby providing an incom-
plete barrier to APOBEC3G and/or APOBEC3F activity. In this
study, we now provide evidence that hypermutated proviral
HIV-1 DNA sequences can be demonstrated by bulk PCR meth-
ods in a signiﬁcant minority of clade B HIV-1-infected individu-
als. Taken together, these data suggest that APOBEC3-mediated
cytidine deamination is highly prevalent but effectively con-
strained by functional interactions with vif, so that G3A hyper-
mutation is generally conﬁned to a minor proportion of the over-
all viral population.
It should be noted that the sequence context targeted by
APOBEC3G appears to speciﬁcally select for loss-of-function
mutations, including within the vif genomic sequence. For ex-
ample, targeted substitutions involving tryptophan residues
(TGG) produce in-frame stop codons (TAG), while the vif
start codon and adjacent aspartic acid residue also create an
APOBEC3G target motif (ATGG) that results in loss of the
methionine initiation signal following G3A substitution. To
some extent, this susceptibility appears to have been overcome
by the utilization of multiple alternative start codons at methi-
onine residues 8, 16, and 29, although it is notable that the
capacity to counteract APOBEC3G activity appears to be lost
as a consequence of these N-terminal truncations (31, 34). In
this study, substitutions associated with truncated vif sequences
could be entirely explained by APOBEC3G-mediated cytidine
deamination (Fig. 5), although it is notable that hypermutation
was associated speciﬁcally with vif in-frame stop codons but not
with in-frame stop codons in non-vif viral peptides. Hence,
while it is difﬁcult to attribute causality in the relationship
between hypermutation and defective vif, the most parsimoni-
ous explanation appears to be provided by a mechanism in
which APOBEC3-mediated G3A substitutions, occurring in a
relatively nonpermissive cellular environment but targeting
TGG trinucleotide motifs stochastically along the genome, can
become unconstrained if this process selects for defective vif
sequences.
Although the translated vif sequences in this cohort were
highly polymorphic (Fig. 4), there were 23 vif amino acid vari-
ants unique to HIV-1 hypermutated sequences, of which 13
associated with HM-3G sequences and three unique to HM-3F
sequences could not have resulted from cytidine deamination
by the relevant APOBEC3 protein (Fig. 5). These data are
consistent with those that suggest the vif N terminus contains
distinct motifs that are likely to interface with APOBEC3G
and APOBEC3F (33, 35) and may therefore represent true vif
allelic variants that facilitate hypermutation. Although the as-
sociated amino acids differed, four of the twenty-three vif





185) occurred at positions previously associated with naturally
occurring nonfunctional vif variants (31).
With reference to the nonhypermutated vif sequences, we
observed polymorphism at residues within key motifs shown to
be required for vif phosphorylation (40), vif-E3 ligase complex
formation (22), vif multimerization (39), and 
-sheet forma-
tion (8). In this study, however, these variants were not asso-
ciated with APOBEC3-mediated hypermutation, suggesting
that polymorphisms within these motifs are tolerated without
signiﬁcantly compromising vif function. While it is unclear if
these polymorphisms alter the efﬁciency of polyubiquitination
and proteasomal degradation of the vif-APOBEC3G-E3 ligase
complex in vivo, the lack of hypermutation in these sequences
could potentially be attributed to an undiminished capacity for
vif-APOBEC3G complex formation, which is sufﬁcient to re-
strict APOBEC3G-mediated hypermutation in vitro (13). De-
spite the high degree of vif polymorphism, several stretches of
conserved residues, most notably the ﬁrst 18 N-terminal amino
acids, were observed and may represent novel drug targets.
The dinucleotide sequence context of the G3A substitu-
tions suggests that APOBEC3G was the dominant contributor
to hypermutation in this study group. These ﬁndings are con-
sistent with the previously mentioned in vivo study by Kieffer et
al., which involved clade B HIV-1 sequences (14). In contrast, two








































































 studies involving Tanzanian study populations infected with pre-
dominantly non-clade B virus (11, 15) indicate less bias towards
the APOBEC3G context. These differences warrant further ex-
ploration, particularly as a nonsynonymous APOBEC3G 186R
polymorphism associated with accelerated progression to
AIDS (and therefore implying loss of APOBEC3G function)
has been found to be frequent in African Americans (37%) but
rare in European Americans (5%) (1). Hence, a relatively
greater contribution of APOBEC3F to HIV-1 cytidine deami-
nase editing may be anticipated in at least some populations of
African origin. In this study, there was no convincing evidence
that APOBEC3G genetic variation contributed to the devel-
opment of HIV-1 hypermutation, and it is notable that we were
unable to identify signiﬁcant amino acid variation within
APOBEC3G sequences in these Caucasian populations (Table
2). A marginal univariate association between an intronic
APOBEC3G 6,892 C allele and hypermutation was demon-
strated, although the role of this intronic polymorphism on
APOBEC3G function is unclear. However it is possible that
functional polymorphisms are located in the as-yet-undeﬁned
promoter or regulatory regions of this genetic locus, and in this
regard it is notable that APOBEC3G mRNA levels in stimu-
lated peripheral blood mononuclear cells have recently been
found to exhibit an inverse correlation with HIV-1 pretreat-
ment viremia (12), though no correlation exists in resting T
cells (5).
In conclusion, this study provides strong support for the
proposition that APOBEC3G-mediated cytosine deamination
provides a potent source of innate HIV-1 restriction at the
population level. Moreover, the prevalence and antiretroviral
impact of APOBEC3G- and APOBEC3F-mediated HIV-1
hypermutation within the study population can be compared
favorably with known host protective factors. Since Sheehy and
colleagues ﬁrst isolated the APOBEC3G gene 4 years ago and
tentatively proposed a cytidine deaminase function for its
product (30), considerable advances in the understanding of
APOBEC3 proteins and their antiviral activity have been
made. We believe that these data contribute to the premise
FIG. 5. Schematic representation of HM and truncated vif proteins identiﬁed in vivo from putative translation of proviral DNA sequences.
Shaded bars indicate translated vif sequences, unshaded bars indicate untranslated vif sequences, and partially shaded bars indicate regions not
sequenced. Red lines indicate unique polymorphisms from consensus that could not be attributed to the corresponding APOBEC3 enzyme, and
blue lines indicate unique polymorphisms from consensus that could potentially be attributed to the corresponding APOBEC3 enzyme. Sequences
are ordered by HM-3G, HM-3F, and NH in descending order according to the consolidated 3G score. Amino acids below the peptides indicate
consensus, and amino acids above the peptides indicate amino acids unique to the individual peptide sequence.








































































 that APOBEC3G comprises a form of innate antiviral resis-
tance that is clinically and biologically relevant and may lend a
fresh perspective to the area of HIV/AIDS therapies (2).
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AUTHOR’S CORRECTION
Population Level Analysis of Human Immunodeﬁciency Virus Type 1
Hypermutation and Its Relationship with APOBEC3G
and vif Genetic Variation
Craig Pace, Jean Keller, David Nolan, Ian James, Silvana Gaudieri, Corey Moore, and Simon Mallal
Centre for Clinical Immunology & Biomedical Statistics, Royal Perth Hospital & Murdoch University, GPO Box X2213, Perth 6847,
Australia; Centre for Forensic Science, School of Anatomy & Human Biology, University of Western Australia, Nedlands, Australia;
and Department of Clinical Immunology & Biochemical Genetics, Royal Perth Hospital, Wellington St., Perth 6000, Australia
Volume 80, no. 18, p. 9259–9269, 2006. Page 9259, Abstract, line 4: delete “near-full-length.”
Page 9259, Materials and Methods, Patient selection, line 3: “(1,000 nucleotides)” should read “(400 nucleotides).”
Page 9260, Materials and Methods, Ampliﬁcation and sequencing of HIV-1 proviral DNA, measurement of pretreatment HIV
RNA levels, and HLA and CCR5 genotyping: Add the following as paragraph 2.
The HIV-1 proviral DNA sequences analyzed in this manu-
script have been deposited in GenBank with the following
sequential accession numbers: EF178299 through EF178434.
The study population from which these sequences were de-
rived overlaps substantially (134 of 136) with that described
in a previous publication (P. Kiepiela, A. J. Leslie, I. Hon-
eyborne, D. Ramduth, C. Thobakgale, S. Chetty, P. Rath-
navalu, C. Moore, K. J. Pfafferott, L. Hilton, P. Zimbwa, S.
Moore, T. Allen, C. Brander, M. M. Addo, M. Altfeld, I.
James, S. Mallal, M. Bunce, L. D. Barber, J. Szinger, C. Day,
P. Klenerman, J. Mullins, B. Korber, H. M. Coovadia, B. D.
Walker, and P. J. Goulder, Nature 432:769–775, 2004). For
this analysis, we were aware that the design of PCR and
sequencing primers has been altered over time to reduce the
ampliﬁcation of hypermutated HIV-1 sequences with large
numbers of G-to-A mutations, so analysis was limited to
sequences that were obtained prior to the use of these alter-
native primers. Instances in which sequences in these two
data sets are derived from a common source are noted in the
relevant GenBank submissions.
We wish to inform the readers that at the time of the submission of this Author’s Correction, missing sequences and gaps are
represented by the International Union of Pure and Applied Chemistry code “N” in GenBank, which can also denote undeter-
mined bases. Note that sequence gaps are annotated as such for each sequence but that the use of sequence formatting tools will
not show annotated gaps. For this reason, the accompanying table includes a summary of the number of bases determined, the
number and percentage of nucleotide mixtures, and the number of undetermined bases (i.e., N’s) for each accession number. The
nine HIV-1 proviral DNA sequences that were excluded from the analysis data are also marked with an asterisk in the table,
indicating sequences with insufﬁcient numbers of substitutions relative to the population consensus to provide stable estimates of
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